A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

March 2, 2021

Study Completion Date

November 30, 2021

Conditions
Psoriasis
Interventions
DRUG

Guselkumab 100 mg

Guselkumab 100 mg will be administered as SC injection.

DRUG

Placebo

Placebo will be administered as SC injection.

Trial Locations (26)

20089

Istituto Clinico Humanitas, Rozzano

22391

MensingDerma research GmbH, Hamburg

23538

Universitätsklinikum Schleswig Holstein Campus Lübeck, Lübeck

28031

Hosp. Univ. Infanta Leonor, Madrid

28041

Hosp. Univ. 12 de Octubre, Madrid

33000

CHU Bordeaux - Hopital St Andre, Bordeaux

46026

Hosp. Univ. I Politecni La Fe, Valencia

46940

Hosp. de Manises, Valencia

48149

Universitaetsklinikum Muenster, Münster

48455

Fachklinik Bad Bentheim, Bad Bentheim

55131

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

56126

Ospedale Santa Chiara AO Universitaria Pisana, Pisa

58453

Centrovital, Witten

60590

Universitatsklinikum Frankfurt, Frankfurt am Main

69437

Hôpital Edouard Herriot, Lyon

76031

Hopital Charles Nicolle, Rouen

95123

P.O. Vittorio Emanuele Azienda Ospedaliero Universitaria 'Policlinico Vittorio Emanuele', Catania

06200

CHU de Nice Hopital de l Archet, Nice

01307

University Hospital Dresden, Dresden

09124

AOU di Cagliari, Cagliari

08916

Hosp. Univ. Germans Trias I Pujol, Badalona

DY1 2HQ

Russell's Hall Hospital, Dudley

LS7 4SA

Chapel Allerton Hospital, Leeds

E11 1NR

Barts Health NHS Trust, London

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

M6 8HD

Salford Royal NHS Foundation Trust, Salford

All Listed Sponsors
lead

Janssen-Cilag Ltd.

INDUSTRY

NCT03998683 - A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis | Biotech Hunter | Biotech Hunter